National Institutes of Health to Grant Exclusive License to PDS Biotechnology Corporation for ME-TARP-Based Immunotherapy

Summary

The National Institutes of Health is considering granting an exclusive patent license to PDS Biotechnology Corporation for the development of a ME-TARP-based immunotherapy, as required by US patent laws.